Comparison of urine neutrophil gelatinase-associated lipocalin and interleukin-18 in prediction of acute kidney injury in adults

Jiadi Gan, BS¹,², Xiaodong Zhou, PhD⁴, *

Abstract

Background: Neutrophil gelatinase-associated lipocalin (NGAL) and interleukin-18 (IL-18) were considered as the most promising biomarkers in prediction of acute kidney injury (AKI), but the priority of them remains unclear.

Methods: Databases of PubMed, Elsevier, Cochrane library, and Web of science were searched until August 23rd, 2017 for studies investigated the diagnostic value of urine NGAL (uNGAL) and urine IL-18 (uIL-18) for AKI in adults. Statistical analysis and investigation of heterogeneity source were using RevMan5.3, MetaDiSc1.40, and Stata14.0.

Results: A total of 7 studies were included involving 2315 patients from 7 countries in this article, of whom 443 (19.1%) developed AKI. The present meta-analysis demonstrated that uNGAL was more valuable compare with uIL-18 with effect size of 1.09 (95% CI 1.03–1.15, P = .004) in specificity, but not in sensitivity with effect size of 1.12 (95% CI 0.98–1.29, P = .104). Subgroup analysis presented that research design may be a foundation affecting the diagnostic accuracy of uNGAL and uIL-18 for AKI. No substantial publication bias was found.

Conclusions: uNGAL is more specific for prediction of AKI in adults as compared with uIL-18.

Abbreviations: AKI = acute kidney injury, AKIN = Acute Kidney Injury Network, AUROC = area under summary receiver operating characteristics curve, CI = confidence interval, ELISA = enzyme-linked immunosorbent assay, FN = false-negative, FP = false-positive, FPR = false positive rate, HSROC = hierarchical summary receiver operating characteristic curves, IL-18 = interleukin-18, KDIGO = Kidney Disease: Improving Global Outcomes, NGAL = neutrophil gelatinase-associated lipocalin, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RIFLE = Risk, Injury, Failure, Loss, End-Stage Kidney Disease, Scr = serum creatinine, TN = true-negative, TP = true positive, TPR = true positive rate.

Keywords: acute kidney injury, interleukin-18, neutrophil gelatinase-associated lipocalin, prediction, urine

1. Introduction

Acute kidney injury (AKI) is a common and serious condition recognized in nearly all fields of medical practice, and over 2 million people are affected by AKI worldwide.¹ The RIFLE (Risk, Injury, Failure, Loss, End-Stage Kidney Disease), modified version AKIN (Acute Kidney Injury Network) criteria, and the KDIGO (Kidney Disease: Improving Global Outcomes), based on serum creatinine (Scr) and urine output, were step forward in diagnosing AKI.²–⁴ A major concern today as the most reliable biomarker for early diagnosis of AKI is to continue to improve.⁵ Clinically, applicable AKI biomarkers should satisfy some certain conditions including rapidly measured by standardized clinical assay platforms, non-invasive, which may decrease patients’ burden like using easily accessible samples, sensitive to facilitate early detection, and specific to differentiate intrinsic AKI from chronic kidney disease and other diseases.⁶–⁷

A number of promising serum and urine biomarkers have recently been characterized to be more sensitive, practical, and accurate in clinical settings, such as neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, kidney injury molecule 1 (KIM-1), and interleukin-18 (IL-18), some of which show brilliant abilities in prediction of AKI.²–⁴ NGAL is a new member of the lipid carrier protein superfamily, which is highly expressed in damaged renal tubules and can be quickly detected in urine.⁸–¹⁰ NGAL is a new member of the lipid carrier protein superfamily, which is highly expressed in damaged renal tubules and can be quickly detected in urine.¹¹,¹² In experimental and clinical studies, NGAL has been investigated extensively and would appear to be one of the most frequently investigated early biomarkers of AKI.¹³–¹⁷ Moreover, a meta-analysis of data from 19 studies including >2500 patients, serum, and urine NGAL levels were found to be diagnostic for AKI.¹⁸ Interleukin 18 (IL-18) is a pro-inflammatory molecule synthesized by phagocytes from the proximal end of the renal tubule,¹⁹,²⁰ having been proposed as a...
promising biomarker for the early detection of AKI in recent years.\textsuperscript{21,22}
Up to date, there is no comparison between these promising biomarkers in the prediction of AKI. Therefore, for the first time, we reported that uNGAL was prior to uIL-18 in specificity.

2. Methods
The search strategy protocol and summarizing the results was presented based on the Cochrane methods for Systematic Reviews of Diagnostic Test Accuracy\textsuperscript{23} and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.\textsuperscript{24}

2.1. Search strategy
We performed a comprehensive literature search of PubMed, Embase, Web of Science, and Cochrane library until August 23, 2017 with the medical subject heading and text words for (“acute kidney injury” OR “acute renal failure” OR “AKI”) AND (“neutrophil gelatinase-associated lipocalin” OR “NGAL”) AND (“Interleukin-18” OR “IL-18”) without language restriction. The reference lists of reviewed full-text articles were checked for fear of losing additional relevant studies. The most recent or complete studies were selected for analysis when the same or similar patient data were included. We used the EndNoteX8 bibliography manager to check the titles and abstracts of all citations and then retrieved and referenced full-text articles. The searches were performed independently by 2 investigators (J.G. and X.Z.). Authors were contacted, where necessary, to provide additional information.

2.2. Selection criteria
The inclusion criteria used for this meta-analysis were as follows: studies investigating the diagnostic accuracy of both uNGAL and uIL-18 to predict AKI; human studies with participants ≥18 years of age; studies with mandatory data from which true-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) could be found or calculated.

2.3. Exclusion criteria
The exclusion criteria used for this meta-analysis were as follows: studies that were systemic review or meta-analysis, animal research, letters, editorials, case reports or case series; studies not available in English; duplicate articles describing the animal research, letters, editorials, case reports or case series; studies that were systemic review or meta-analysis, and excluding diagnosis. The QUADAS-2 sheet was created by RevMan5.3 according to the following bias domains: selection, performance/detection, attrition, and reporting bias. Data were extracted independently according to the selection and exclusion criteria above. Repetitive articles were removed using EndNoteX8 (Thomson Reuters Company) software and the results were pooled. Two authors (JG and XZ) independently determined study eligibility by reviewing each of the citations and retrieving the literature by titles or abstracts. Subsequently, the full texts and disagreements between reviewers on any item were resolved by face-to-face discussion. Results of the search were recorded in a checklist according to the guidelines designed by PRISMA statement.\textsuperscript{25} From each study, the following information was received: first author, country of origin, study design, sample size, population setting, assessment assay, and patient characteristics (age and sex), as well as the definition of AKI. In addition, specificity, sensitivity, area under summary receiver operating characteristics curve (AUROC) with 95% confidence interval (CI) and the optimal cut-off thresholds, which were optional. We calculated the TP, TN, FP, and FN if lacked. If only the data could not be extractable from the article, we contacted the corresponding authors by email and asked whether they were willing to share the information. If no reply was received, the study was excluded from the meta-analysis and included in the descriptive analysis only.

2.5. Statistical analysis
The Spearman correlation coefficient calculated by Meta-DiSc1.40 was used to explore the threshold effect between the pooled sensitivity and 1-specificity. The result indicates nonexistence when the value is negative. The positive result or $P<.05$ indicated the existence of a threshold effect\textsuperscript{26} (differences in sensitivity and specificity occurring because of different cut-offs used in different studies to define a positive test result). Effect size presented the diagnostic ratio of uNAGL versus uIL-18 and likelihood ratio was calculated based on the pooled sensitivity and specificity. Based on the bivariate mixed-effects regression model that was developed by Van Houwelingen et al,\textsuperscript{27} command media was used to calculate effect size of sensitivity, specificity, and area under summary receiver operating characteristics curve. Heterogeneity caused by non-threshold effects was calculated by the $X^2$-based Q test and the inconsistency index $I^2$. Included studies were homogeneous when the statistical significance is set at $P>.10$. The $I^2$ index measured indicates the degree of heterogeneity between multiple studies. $I^2$ values <25%, of 25% to 50%, and >50% indicated modest, moderate, and substantial heterogeneity, respectively.\textsuperscript{28} Besides, hierarchical summary receiver operating characteristic curves (HSROC) was also constructed in this analysis by using the metandi command, which can explain TPR (true positive rate) and FPR (false positive rate) intra- and inter-study variation more accurately.\textsuperscript{29} Remarkable heterogeneity was explored further by subgroup analysis restricted by different study design, description of “gold standard,” sample size, location, clinical setting, and measurement assay. In addition, Deeks funnel plot asymmetry test was used for evaluation of publication bias.\textsuperscript{30} All analysis above expects Spearman correlation coefficient was conducted with StatX (version 14.0).

3. Results
3.1. Search results and study characteristics
The search initially yielded 1079 articles from various databases, of which 143 were excluded by EndnoteX8 because of duplication. After screening through the titles and abstracts, we excluded 845 studies as not relevant to our interests. Having
reviewed the full text of the remaining studies, a total of 7 studies that included 2,315 patients met the inclusion criteria and were included in the meta-analysis (Fig. 1).

Characteristics of individual studies were listed in Table 1. There were 6 prospective cohort studies and 1 case-control studies included in this meta-analysis. Although the eligible studies were published in English, they represented an international experience conducted in a large range of countries including Taiwan, Australia, America, Germany, Spain, Japan, and China, with the publication years ranging from 2008 to 2014. Four studies focused on patients undergoing cardiopulmonary bypass surgery, and the other included living-donor liver transplantation, ICU patients, and emergency department patients. The sample sizes varied between 31 and 1,234 patients. All studies stored samples at −80°C. Measurements methods most commonly used commercial enzyme-linked immunosorbent assay (ELISA) and 1 study used a standardized clinical laboratory platform (ARCHITECT [Abbott Diagnostics]) for urine NGAL and IL-18. Mean age ranged from 38 to 68 years in these studies. Variable definitions of AKI were adopted in the original studies. Five studies defined AKI using AKIN and/or RIFLE criteria. One using Scr level, which diagnosed by the attending physicians or nephrologists, and not fully according to the AKIN criteria in which AKI basically defined as an increase in Scr level of 50% within continuous 96 hours regardless the blood levels of tacrolimus was higher and/or lower than the target range. The definition used for AKI in the last study included, is not clear.

### 3.2. Quality assessment

Supplement 1, http://links.lww.com/MD/C516 showed Spearman correlation coefficient of these 7 articles was −0.536 and 0.071 for uNGAL and uIL-18, respectively (P = .215 and P = .867), suggesting there was no significant threshold effect in different studies. The risk of bias for patient selection, index test, reference standard, and flow and timing, as well as concerns about the applicability related to the first 3 domains were shown in Fig. 2. Several studies did not clearly delineate the selection criteria. Incomplete operationalization of the chosen reference standard for AKI (RIFLE, AKIN, or other) was evident in some of the studies. Other categories mostly showed a low risk of bias. Deeks test showed P value of .71 and .19 for uNGAL and uIL-18, respectively, which indicated the absence of publication bias (Fig. 3).

### 3.3. Data extraction and calculation

The data from 7 eligible studies were extracted and were presented in Table 2, including the measurement timing for the diagnosis of AKI, TP/FP/FN/TN values, various optimal cut-off values for different sample types of NGAL, sensitivities, and...
specificities as well as AUROC (95% CI). For the studies which didn’t provide TP/FP/FN/TN values, we calculated these indexes from provided sensitivity, specificity, and sample size values.

3.4. Diagnostic performance

The forest plots and pooled estimates of sensitivity and specificity were presented in Fig. 4. The pooled effect size of uNGAL measurements to uIL-18 in prediction of AKI was 1.12 (95% CI 0.98–1.29, \( P = .104 \)) in sensitivity and 1.09 (95% CI 1.03–1.15, \( P = .004 \)) in specificity. AUCROC of uNGAL is 0.87 (95% CI 0.84–0.90) and 0.71 (0.67–0.75) for uIL-18, as showed that there was a difference of AUCROC between uNGAL and uIL-18 and 95%CI of AUCROC between them was non-overlapping (Supplement 2, http://links.lww.com/MD/C516). The pooled positive likelihood ratio of uNGAL was 4.87, indicating that the possibility of an uNGAL test leading to a correct diagnosis for positive results was 4.87 times higher than that of making a

| Study          | Location     | Design | Setting    | Storage (°C) | uNGAL assay | uIL-18 assay | Mean age (y) | Male (%) | AKI definition                      |
|----------------|--------------|--------|------------|--------------|-------------|--------------|--------------|----------|-------------------------------|
| Chen et al[31] | Taiwan       | PC     | CCU        | –80          | ELISA       | ELISA        | 66 ± 1       | 75.3     | AKIN criteria                   |
| Endre et al[32] | Australia    | PC     | ICU        | –80          | ELISA       | ELISA        | 69 ± 17      | 69.2     | AKIN or RIFLE criteria          |
| Nickolas et al[33] | Germany   | PC     | ED         | –80          | Clinical†   | Clinical†    | 64           | 52.3     | RIFLE creatinine R or worse     |
| Torregrosa et al[34] | Spain      | PC     | CAG        | –80          | ELISA       | ELISA        | 67           | 75.3     | RIFLE criteria                   |
| Tsuchimoto et al[35] | Japan      | PC     | LDLT       | –80          | ELISA       | ELISA        | 68           | 73.9     | Increase in Scr ≥50% within 96 h |
| Vaidya et al[36] | America      | CC     | ICU        | –80          | ELISA       | ELISA        | 61.2 ± 17.2  | 55       | RIFLE creatinine R or worse     |
| Xin et al[37] | China        | PC     | CS         | –80          | ELISA       | ELISA        | 38.3         | 54.5     | NA                             |

AKI = acute kidney injury, AKIN = Acute Kidney Injury Network, CAG = coronary angiography, CC = Case-control, CCU = coronary care unit, CIN = contrast-induced nephropathy, CS = cardiac surgery, ED = emergency department, ELISA = enzyme-linked immunosorbent assay, ICU = intensive care unit, LDLT = living-donor liver transplantation, NA = not available, PC = prospective cohort, RIFLE = risk, injury, failure, loss, end-stage renal disease. †Clinical Standardized clinical laboratory platforms (ARCHITECT assay).

Figure 2. Quality assessment of the 7 eligible studies using QUADAS-2. QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies-2.
wrong diagnosis for positive results. The pooled negative likelihood ratio indicated in contrast, and similarly with uIL-18 as showed in Supplement 3, http://links.lww.com/MD/C516. The AUROC indicated good, but not brilliant diagnostic accuracy.

All the results except the sensitivity above revealed a more diagnostic accuracy of uNGAL to uIL-18 in screening out AKI.

Distribution of accurate estimator points in the plots did not show a “shoulder arm” pattern (Supplement 2, http://links.lww.com/MD/C516), suggesting no presence of the threshold effect, which was corresponding with the result of Spearman correlation coefficient.

In addition, subgroup analysis showed that consistency of non-prospective studies had significantly been decreased (Supplement

### Table 2: Diagnostic value of NGAL and IL-18 to predict AKI in individual studies.

| Study | Time of measurement | Biomarker | TP | FP | FN | TN | Cutoff | Sensitivity | Specificity | AUROC |
|-------|---------------------|-----------|----|----|----|----|--------|-------------|-------------|--------|
| Chen et al[31] | Within 24h of CCU admission | A | 28 | 17 | 15 | 90 | 33 | 0.65 | 0.84 | 0.8 |
| | | B | 22 | 17 | 23 | 90 | 70 | 0.49 | 0.84 | 0.63 |
| Entre et al[32] | On admission | A | 59 | 76 | 88 | 305 | 41 | 0.4 | 0.8 | 0.66 |
| | | B | 50 | 84 | 97 | 297 | 36 | 0.34 | 0.78 | 0.62 |
| Nickolas et al[33] | Within 12h of ED admission | A | 65 | 216 | 31 | 922 | 104 | 0.68 | 0.81 | 0.81 |
| Torregrosa et al (CAG)[34] | 12h after CAG | A | 56 | 398 | 40 | 740 | 36 | 0.58 | 0.65 | 0.64 |
| | | B | 8 | 21 | 4 | 56 | 202 | 0.67 | 0.73 | 0.73 |
| Torregrosa et al (CS)[34] | 12h after CS | A | 9 | 6 | 5 | 26 | 31 | 0.64 | 0.81 | 0.77 |
| | | B | 9 | 13 | 5 | 19 | 249 | 0.64 | 0.59 | 0.68 |
| Tsuchimoto et al[35] | On postoperative days 7, 14, and 21 | A | 16 | 2 | 4 | 9 | 61 | 0.8 | 0.82 | 0.87 |
| | | B | 9 | 1 | 11 | 10 | 13.6 | 0.45 | 0.91 | 0.60 |
| Vaidya et al[36] | NA | A | 82 | 4 | 20 | 98 | 82.7 | 0.8 | 0.96 | 0.89 |
| | | B | 69 | 5 | 33 | 97 | 2.74 | 0.68 | 0.95 | 0.83 |
| Xin et al[37] | 2h after CS | A | 6 | 6 | 3 | 18 | 250 | 0.67 | 0.75 | 0.84 |
| | | B | 7 | 2 | 2 | 22 | 2.200 | 0.78 | 0.92 | 0.89 |

A = uNGAL, AKI = acute kidney injury, AUROC = area under the receiver operating characteristic curve, B = uIL-18, CAG = coronary angiography, CCU = coronary care unit, CN = contrast-induced nephropathy, CPB = cardiopulmonary bypass, CS = cardiac surgery, ED = emergency department, FN = false negative, FP = false positive, NA = not available, TN = true negative, TP = true positive.

Ng/mg.

"ng/mg."

"pg/mL/mmol/L Cr.

"pg/mL/mmol/L Cr."
indicating the parameter prodesign may be a factor of heterogeneity in the included studies. The results of uNGAL in hierarchical summary receiver operating characteristic model presented $b - 0.51$ (95% CI $-0.4$ to $-1.44$, $Z = -1.09$, $P = .274$) that reflected the SROC was symmetric, and the effect index representing discriminant ability $\lambda = 2.96$ (95% CI $1.86$ to $4.05$), prompting a moderate diagnostic value of uNGAL for AKI. Similarly, $b$ was $0.51$ (95% CI $-0.43$ to $1.44$, $Z = 1.06$, $P = .289$) for uIL-18 also reflected symmetric SROC and $\lambda = 1.41$ (95% CI $0.53$ to $2.29$) prompted a moderate diagnostic value (Fig. 5, Supplement 5, http://links.lww.com/MD/C516). Obviously, uNGAL was more significantly valuable than uIL-18 that had been verified in this model.

4. Discussion

More recently, numerous clinical studies have focused on the diagnostic accuracy of biomarkers in predicting AKI since accumulating evidence demonstrating the weak ability of “gold standard” SCr level.[18] Among these promising biomarkers approved lately, NGAL and IL-18 were understanding as a quick, accurate, and precise marker of genomic, transcriptomic, and proteomics techniques,[29,18] which implies that they could become a practical clinical test for diagnosis of AKI. IL-18 is synthesized as an inactive 23-kDa precursor mainly in proximal tubular epithelial cells and getting into tubular fluid after activated. Our choice for urine NGAL but not plasma or serum was in order to avoid the heterogeneity between blood and urine samples. Therefore, we only included the initial researches with needed data containing both uNGAL and uIL-18. Substantial studies existed only considering single uNGAL or uIL-18 were excluded.

Overall, the present meta-analysis has shown the superiority of uNGAL levels to uIL-18 for predicting the progression of AKI, which was demonstrated by the above values including the effect size of specificity, positive likelihood ratio, negative likelihood ratio, AUROC, and even the Lambda of HSROC.

One limitation of this analysis was the heterogeneity with these studies based on different institutions across the world. Meanwhile, varying time of biomarkers measurement, different definitions and various settings of AKI were used in the individual studies. For a predictive biomarker, it is important to determine the cutoff value between the health and disease group. However, we could not calculate the ideal cutoff value of uNGAL or uIL-18 for lack of raw data. We wish to finish it in our continued study. Threshold effects induced by variable cutoff values of the included studies may lead to the heterogeneity. But our analysis did not present the threshold effects. The cause of non-threshold
effects maybe the design of studies (non-prospective ones reduce
diagnostic effect both of uNGAL and uIL-18) and the study conducted by Liangos et al[39] which raised integral value of uNGAL. Included studies in this meta-analysis were constructed with a wide range of clinical settings. Our result is applicable with great most patients to a certain extent. However, AKI is also a defect associated with other comorbidities such as diabetes, arteriosclerosis, and higher immunological experience, which interfered with the sensitivity and specificity of the diagnostic test. Finally, the statistical approach used in this study is not capable of considering the different AKI severity stages on the analysis of the accuracy of the biomarkers.

The main strength of our study is that it appears to be the first analysis comparing the diagnostic performance of uNGAL and uIL-18 directly by using this statistical approach, which make it authentic and reliable.

5. Conclusions

The present meta-analysis demonstrated that uNGAL was more accurate specifically than uIL-18 in early diagnosis of AKI. Due to restrictive studies be analyzed in this study, more future randomized controlled trials across a broad spectrum of clinical settings with larger sample sizes are needed to validate this issue.

Author contributions

All authors have contributed significantly, Jiadi Gan was mainly responsible for the statistical analysis, and Xiaodong Zhou prepared the manuscript. And that all authors are in agreement with the content of the manuscript.

Funding acquisition: Xiaodong Zhou.
Investigation: Jiadi Gan.
Methodology: Jiadi Gan.
Resources: Jiadi Gan, Xiaodong Zhou.
Software: Jiadi Gan.
Writing – original draft: Jiadi Gan.
Writing – review & editing: Jiadi Gan.
Jiadi Gan orcid: 0000-0002-1256-8950

References

[1] Ali T, Roderick P. Epidemiology of Acute Kidney Injury. Springer, Berlin Heidelberg, 2010.
[2] Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006;10:R73.

[3] Mehta R, Kellum J, Shah S, et al. Acute Kidney Injury Network: Report Of An Initiative To Improve Outcomes In Acute Kidney Injury. Vol 113; 2007.

[4] Leve A, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089–100.

[5] Libório AB, Bezerra CTD. Acute kidney injury in neonates: from urine output to new biomarkers. Biomed Res Int 2014;2014:601568.

[6] Mai TN, Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr 2011;23:194–200.

[7] Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol 2007;156:203–12.

[8] Vanmassenhove J, Vanholder R, Nagler E, et al. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant 2013;28:254–73.

[9] Parés L, Cunha Júnior AD, Schafé AJ, et al. Biomarkers of acute kidney injury. J Bras Nefrol 2013;35:289–36.

[10] Sirotka JC, Klawitter J, Edelstein CL. Biomarkers of acute kidney injury. J Toxicol 2011;2011:328120.

[11] Devarajan P. Neutrophil gelatinase-associated lipocalin—an emerging troponin for kidney injury. Nephrol Dial Transplant 2008;23:3737–43.

[12] Haase M, Bellomo R, Haase-Fielitz A. Neutrophil gelatinase-associated lipocalin. Curr Opin Crit Care 2010;16:526.

[13] Mishra J, Dent C, Tatarishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;361:1231–8.

[14] Nicolòs DTL, O’Rourke MJ, Yang DJ, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008;148:810–9.

[15] Tuladhar SM, PáNtnmann VO, Soni M, et al. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharmacol 2009;53:261–6.

[16] Shapiro NI, Trzcinski S, Hollander JE, et al. The diagnostic accuracy of plasma neutrophil gelatinase-associated lipocalin in the prediction of acute kidney injury in emergency department patients with suspected sepsis. Ann Emerg Med 2010;56:52–9.

[17] Valette X, Savary B, Nowoczyzn M, et al. Accuracy of plasma neutrophil gelatinase-associated lipocalin in the early diagnosis of contrast-induced acute kidney injury in critical illness. Intensive Care Med 2013;39:837–65.

[18] Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:1012–24.

[19] Melnikov VY, Eder T, Fantuzzi G, et al. Impaired IL-18 processing protects caspase-1–deficient mice from ischemic acute renal failure. J Clin Invest 2001;107:1145–52.

[20] Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73:213–24.

[21] Liu Y, Guo W, Zhang J, et al. Urinary Interleukin 18 for detection of acute kidney injury: a meta-analysis. Am J Kidney Dis 2013;62:1058–67.

[22] Lin X, Yuan J, Zhao Y, et al. Urine interleukin-18 in prediction of acute kidney injury: a systemic review and meta-analysis. J Nephrol 2015;28:7–16.

[23] Available at: http://srdata.cochrane.org/handbook-dta-reviews.

[24] Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD Statement. JAMA 2015;313:1637–65.

[25] Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.

[26] Araujo LR, Hamza TH, Houwelingen JC, et al. Bivariate random effects meta-analysis of ROC curves. Med Decis Making 2008;28:621–18.

[27] Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002;21:389–624.

[28] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.

[29] Chappell FM, Raab GM, Wardlaw JM. When are summary ROC curves appropriate for diagnostic meta-analyses? Stat Med 2009;28:2653–68.

[30] Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882–93.

[31] Chen TH, Chang CH, Lin CY, et al. Acute kidney injury biomarkers for patients in a coronary care unit: a prospective cohort study. PLoS One 2012;7:e32328.

[32] Endre ZH, Pickering JW, Walker RJ, et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int 2011;79:1119–30.

[33] Nickellos TL, Kai SO, Pietro C, et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol 2012;59:246–53.

[34] Torregrosa I, Montoliu C, Utrio A, et al. Early biomarkers of acute kidney failure after heart angiography or heart surgery in patients with acute coronary syndrome or acute heart failure. Nefrologia 2012;32:44–52.

[35] Tsuchimoto A, Shinkle H, Uesugi M, et al. Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. PLoS One 2014;9:e110527.

[36] Vaida VY, Waikar SS, Ferguson MA, et al. Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. J Am Coll Cardiol 2012;59:246–53.

[37] Xin C, Yulong X, Yu C, et al. Urine neutrophil gelatinase-associated lipocalin and interleukin-18 predict acute kidney injury after cardiac surgery. Renal Fail 2008;30:904–13.

[38] Greenier FC, Ali S, Svej H, et al. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability. Clin Biochem 2010;43:615–20.

[39] Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009;14:423–31.